Scope and Impact of Financial Conflicts of Interest in Biomedical Research

The objectives of this study were to assess the reporting quality of randomized controlled trial (RCT) abstracts published in leading laser medicine journals, and investigate the association between potential predictors and reporting quality. A total of 129 RCT abstracts were included and assessed. The mean OCS was 4.5 (standard deviation, 1.3). Only three quality items (interventions, objective, conclusions) were reported adequately in most abstracts (>80%). No abstract adequately reported results for the primary outcome, source of funding, and status of the trial. In addition, sufficient reporting of participants, outcome in the methods section, randomization, and trial registration was rare (<5%). According to multivariable linear regression analysis, the specialty area of RCT abstracts was significantly associated with their reporting quality (P=0.008).The reporting quality of RCT abstracts published in leading laser medicine journals is suboptimal. Joint efforts by authors, editors and other stakeholders in the field to improve trial abstract reporting are needed.

show abstract

“…[20,21] Besides, if a trial is funded by the industry, its results could be biased in favor of the sponsor [22,23].…”

Section: Reporting Of Items Related To Biases In Rctsmentioning

confidence: 99%

Reporting quality of randomized controlled trial abstracts published in leading laser medicine journals: an assessment using the CONSORT for abstracts guidelines

2016

View full text Add to dashboard Cite

show abstract

“…However, as with any financial relationships with industry, there are risks for conflicts of interest and bias [2,5,6,20,22,25,30,38,43]. As a result, increased transparency in these relationships has been stressed.…”

Section: Introductionmentioning

confidence: 99%

Orthopaedic Surgeons Receive the Most Industry Payments to Physicians but Large Disparities are Seen in Sunshine Act Data

Samuel

Webb

Lukasiewicz

et al. 2015

Clin Orthop Relat Res

View full text Add to dashboard Cite

Background Industry payments made to physicians by drug and device manufacturers or group purchasing organizations are now reported to the Centers for Medicare and Medicaid Services (CMS) as a part of the Physician Payments Sunshine Act. Initial reports from the program show that orthopaedic surgeons lead all physician specialties in total and average industry payments. However, before further discussion of these payments and their implications can take place, it remains to be seen whether these figures are a true reflection of the field of orthopaedic surgery in general, rather than the result of a few outlier physicians in the field. In addition, the nature and sources of these funds should be determined to better inform the national dialogue surrounding these payments.

show abstract

“…All this largesse translates into, as of 2001, 80,000 clinical trials going on in the U.S., with 2.3 million Americans having served as subjects [8]. Up to one quarter of academic investigators in biomedical research receive industry funding [9]. Accompanying this alarming statistic is that almost half of investigators received research related gifts, items definitely not integral to the research process.…”

Section: "He Who Would Do a Great Evil Must First Of All Convince Himmentioning

confidence: 99%

“…And finally, a recent meta-analysis of eight articles, that together compiled a total of 1140 studies, showed a robust 3.6 odds ratio (95% C.I. 2.6-4.9) favoring pro-industry conclusions when sponsorship was from industry [9]. All this overwhelming data suggests that industry funding definitely creates a powerful, potential bias within the methodology of any clinical research trial.…”

Section: "He Who Would Do a Great Evil Must First Of All Convince Himmentioning

confidence: 99%

“…But below the surface we need to be wary of undue influence on the final results of a study. Pharmaceutical firms have been accused of unfairly stacking studies, partly by restricting publication and data sharing [9]. For example, in May 1999, as lead investigator, Dr. James Kahn halted a study involving over 2500 patients and 77 hospitals because the study drug, Remune (an immunologic modifier) failed to halt the progress of HIV disease [17].…”

Section: "He Who Would Do a Great Evil Must First Of All Convince Himmentioning

confidence: 99%

See 1 more Smart Citation

Conflicts of interest: Bias or boon?

Tomaszewski

2006

J. Med. Toxicol.

View full text Add to dashboard Cite

Scope and Impact of Financial Conflicts of Interest in Biomedical Research

Abstract: Dr Gross has served as a consultant and scientific advisory board member to Astra-Zeneca. Mr Bekelman has served as a consultant to Turbogenomics Inc.

Cited by 1,658 publications

References 86 publications

Reporting quality of randomized controlled trial abstracts published in leading laser medicine journals: an assessment using the CONSORT for abstracts guidelines

Reporting quality of randomized controlled trial abstracts published in leading laser medicine journals: an assessment using the CONSORT for abstracts guidelines

Orthopaedic Surgeons Receive the Most Industry Payments to Physicians but Large Disparities are Seen in Sunshine Act Data

Conflicts of interest: Bias or boon?

Contact Info

Product

Resources

About